Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Schatz is active.

Publication


Featured researches published by Michael Schatz.


The New England Journal of Medicine | 2011

Daily or Intermittent Budesonide in Preschool Children with Recurrent Wheezing

Robert S. Zeiger; David T. Mauger; Leonard B. Bacharier; Theresa W. Guilbert; Fernando D. Martinez; Robert F. Lemanske; Robert C. Strunk; Ronina A. Covar; Stanley J. Szefler; Susan J. Boehmer; Daniel J. Jackson; Christine A. Sorkness; James E. Gern; H. William Kelly; Noah J. Friedman; Michael Mellon; Michael Schatz; Wayne Morgan; Vernon M. Chinchilli; Hengameh H. Raissy; Elizabeth Bade; Jonathan Malka-Rais; Avraham Beigelman; Lynn M. Taussig

BACKGROUND Daily inhaled glucocorticoids are recommended for young children at risk for asthma exacerbations, as indicated by a positive value on the modified asthma predictive index (API) and an exacerbation in the preceding year, but concern remains about daily adherence and effects on growth. We compared daily therapy with intermittent therapy. METHODS We studied 278 children between the ages of 12 and 53 months who had positive values on the modified API, recurrent wheezing episodes, and at least one exacerbation in the previous year but a low degree of impairment. Children were randomly assigned to receive a budesonide inhalation suspension for 1 year as either an intermittent high-dose regimen (1 mg twice daily for 7 days, starting early during a predefined respiratory tract illness) or a daily low-dose regimen (0.5 mg nightly) with corresponding placebos. The primary outcome was the frequency of exacerbations requiring oral glucocorticoid therapy. RESULTS The daily regimen of budesonide did not differ significantly from the intermittent regimen with respect to the frequency of exacerbations, with a rate per patient-year for the daily regimen of 0.97 (95% confidence interval [CI], 0.76 to 1.22) versus a rate of 0.95 (95% CI, 0.75 to 1.20) for the intermittent regimen (relative rate in the intermittent-regimen group, 0.99; 95% CI, 0.71 to 1.35; P=0.60). There were also no significant between-group differences in several other measures of asthma severity, including the time to the first exacerbation, or adverse events. The mean exposure to budesonide was 104 mg less with the intermittent regimen than with the daily regimen. CONCLUSIONS A daily low-dose regimen of budesonide was not superior to an intermittent high-dose regimen in reducing asthma exacerbations. Daily administration led to greater exposure to the drug at 1 year. (Funded by the National Heart, Lung, and Blood Institute and others; MIST ClinicalTrials.gov number, NCT00675584.).


Archive | 1998

Asthma and immunological diseases in pregnancy and early infancy

Michael Schatz; Robert S. Zeiger; Henry N. Claman


The Journal of Allergy and Clinical Immunology | 2000

Effect of allergist intervention on patient-centered and societal outcomes : Allergists as leaders, innovators, and educators

Robert S. Zeiger; Michael Schatz


Archive | 2002

Immediate Hypersensitivity to Methylparaben Causing False-Positive Results of Local Anesthetic Skin Testing or Provocative Dose Testing

Eric Macy; Michael Schatz; Robert S. Zeiger


Medical Clinics of North America | 1981

Immunotherapy of Atopic Disorders: Present State of the Art and Future Perspectives

Robert S. Zeiger; Michael Schatz


Middleton's Allergy (Eighth Edition) | 2014

58 – Asthma and Allergic Diseases during Pregnancy

Michael Schatz; Robert S. Zeiger; Reuben Falkoff; Christina D. Chambers; Eric Macy; Michael Mellon


Proceedings of the American Thoracic Society | 2012

Follow-up after Acute Asthma Episodes

Michael Schatz; Gary S. Rachelefsky; Jerry A. Krishnan


Journal of Asthma | 1983

Immunologic Approach to the Management of Asthma

Robert S. Zeiger; Michael Schatz


/data/revues/00916749/v131i2/S0091674912016909/ | 2013

Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis

Eli O. Meltzer; Michael Schatz; Robert A. Nathan; Cindy Garris; Richard H. Stanford; Mark Kosinski


/data/revues/00916749/unassign/S0091674913015546/ | 2013

Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma

Michael Schatz; Jin-Wen Y. Hsu; Robert S. Zeiger; Wansu Chen; Alejandro Dorenbaum; Bradley E. Chipps; Tmirah Haselkorn

Collaboration


Dive into the Michael Schatz's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Avraham Beigelman

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge